0001209191-12-002549.txt : 20120106
0001209191-12-002549.hdr.sgml : 20120106
20120106161246
ACCESSION NUMBER: 0001209191-12-002549
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20120104
FILED AS OF DATE: 20120106
DATE AS OF CHANGE: 20120106
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: REYNOLDS FRANCIS
CENTRAL INDEX KEY: 0001503383
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-52089
FILM NUMBER: 12514752
MAIL ADDRESS:
STREET 1: ONE BROADWAY
STREET 2: 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INVIVO THERAPEUTICS HOLDINGS CORP.
CENTRAL INDEX KEY: 0001292519
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 000000000
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE BROADWAY
STREET 2: 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (617) 475-1520
MAIL ADDRESS:
STREET 1: ONE BROADWAY
STREET 2: 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Design Source, Inc.
DATE OF NAME CHANGE: 20040602
4
1
c26597_4x0.xml
MAIN DOCUMENT DESCRIPTION
X0304
4
2012-01-04
0001292519
INVIVO THERAPEUTICS HOLDINGS CORP.
NVIV
0001503383
REYNOLDS FRANCIS
C/O INVIVO THERAPEUTICS HOLDINGS CORP.
ONE BROADWAY, 14TH FLOOR
CAMBRIDGE
MA
02142
1
1
1
0
CEO, CFO
COMMON STOCK, $0.00001 PAR VALUE
2012-01-04
4
S
0
44497
2.6247
D
14853163
D
COMMON STOCK, $0.00001 PAR VALUE
2012-01-05
4
S
0
109000
2.6310
D
14744163
D
COMMON STOCK, $0.00001 PAR VALUE
2012-01-06
4
S
0
96503
2.5323
D
14647660
D
COMMON STOCK, $0.00001 PAR VALUE
13603
I
By 401(k) Plan
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.60 to $2.70, inclusive. The reporting person undertakes to provide InVivo Therapeutics Holdings Corp. ("InVivo"), any security holder of InVivo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1, 2 and 3 of this Form 4.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.55 to $2.7035, inclusive.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 to $2.60, inclusive.
Between October 1 and December 31, 2011, the reporting person acquired 13,603 shares of InVivo Therapeutics Holdings Corp. common stock under a 401(k) plan. The information in this report is based on a plan statement dated as of December 31, 2011.
/S/ ELIZABETH FRASER, AS ATTORNEY IN FACT
2012-01-06